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In recent decades, a classic recipe in traditional Chinese medicine, Guilu erxian jiao (GEJ), has been used
in the prevention and treatment of myelosuppression following cancer chemotherapy. However, the
safety and efficacy of GEJ has not been studied. In the present study, we investigated the safety and
efficacy of GEJ in the management of myelosuppression in a cohort of advanced lung adenocarcinoma
patients who received 4 cycles of chemotherapy. Treatment with GEJ was compared to the conventional
treatment with pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF). The
GEJ treatment group (38 patients) was orally administered GEJ whilst the control group (25 patients)
were treated with PEG-rhG-CSF during the 4 cycles of chemotherapy. We found that GEJ was as safe as
the recommended treatment, PEG-rhG-CSF. GEJ patients recovered from suppressed bone marrow in a
much steadier approach, compared with the highly fluctuating changes observed in PEG-rhG-CSF
treatment. Our data suggests that GEJ may be a better alternative to manage cancer chemotherapy-
induced myelosuppression.
© 2020 The Authors. Production and hosting by Elsevier B.V. on behalf of KeAi Communication Co., Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
Myelosuppression, related to dysfunction of blood cell produc-
tion, is one of the most serious side-effects of chemotherapy.1,2
Serious myelosuppression and hematologic toxicities following
chemotherapies are major reasons for mortality and morbidity,n), sunbaoguo666@126.com
nications Co., Ltd.
vier on behalf of KeAi
ing by Elsevier B.V. on behalf of K
d/4.0/).thus placing limitations on dose intensification and optimization of
drug treatments for cancer patients.3 Currently granulocyte colony-
stimulating factor (G-CSF), usually administered as pegylated re-
combinant human G-CSF (PEG-rhG-CSF), is the recommended
treatment for primary and/or secondary prophylaxis before
commencement of chemotherapy regimens. However, the use of G-
CSF usually posts high risk of febrile neutropenia (FN).4 Hence,
finding alternative approaches to effectively prevent and treat bone
marrow suppression during chemotherapy for cancer patients is
important.
A classic recipe in traditional Chinese medicine (TCM), Guilu
erxian jiao (GEJ), has been used to treat anemia and related
disorders in China for thousands of years.5 In recent decades, GEJ
has also been used in the prevention and treatment of myelo-
suppression following cancer chemotherapy. However, the safety
and efficacy of GEJ has not been studied.6,7 Therefore, in the
present study, we investigated the safety and efficacy of GEJ ineAi Communication Co., Ltd. This is an open access article under the CC BY-NC-ND
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lung adenocarcinoma patients who received 4 cycles of
chemotherapy.2. Patients and methods
2.1. Patients and data collection
A total of 38 patients with advanced (IIIB-IV) lung adenocarci-
noma admitted to the First Affiliated Hospital of Sun Yat-Sen Uni-
versity between January and December 2018 were included in the
study. These patients were treated with 4 cycles of chemotherapy,
and Chinese medicine GEJ was used to prevent and treat bone
marrow suppression from the first cycle of chemotherapy. Twenty-
five patients with similar diagnosis, pathology, stage of disease,
demographic characteristics, and chemotherapy regimens who did
not receive GEJ treatment and were treated with PEG-rhG-CSF
formed the control group. The study was approved by the Human
Ethic Committee of the First Affiliated Hospital of Sun Yet-sen
University and all clinical data were extracted and collected ac-
cording to the guidelines set out by the Committee. The study was
also registered with Clinicaltrials.gov (NCT02737735).2.2. Diagnosis
Diagnosis was made according to the 2015 NCCN Guidelines for
the Diagnosis and Treatment of Non-small Cell Lung Cancer.8 As
shown below, WHO classification of toxic and side effects of anti-
tumor drugs was used as the criteria for the classification of bone
marrow suppression.0 I II III Ⅳ
WBC (109/L) 4.0 3.0e3.9 2.0e2.9 1.0e1.9 <1.0
PLT (109/L) 100e300 75e100 50e74.9 25e49.9 <25
HGB (g/L) 120 100e120 80e99 6.5e7.9 <65
Table 1
Comparison of baseline information from 2 groups.
Group N M/F Age IIIB (%) IV (%) Smoking Index
GEJ Group 38 2.78 56.04 ± 9.5 47.1 52.9 150 (0e2500)
G-CSF Group 25 3.54 57.37 ± 10.8 52.5 47.5 400 (0e2400)
Note: P > 0.05.2.3. Inclusion and exclusion criteria
2.3.1. Inclusion criteria
Patients with stage IIIB or IV lung adenocarcinoma confirmed by
histology or cytology; age> 18 years; no gender restriction; ECOG
(Eastern Cooperative Oncology Group) performance status (PS) < 2
points; white blood cell count 1.9  109/L, neutrophil 1  109/L,
hemoglobin 80g/L, platelets 50  109/L; Serum alanine amino-
transferase (ALT), aspartate aminotransferase (AST)  2 times the
normal value, bilirubin and serum creatinine (SCr) levels within the
normal range; ECG and other examinations were normal; and pa-
tients agreed to complete 4 cycles of chemotherapy; and agreed to
receive GEJ or G-CSF treatment.Table 2
Toxicity of GEJ measured as liver and kidney functions at the end of treatment.
Items Unit GEJ Group G-CSF Group F P value
ALT U/L 31.2 ± 7.6 33.7 ± 11.2 0.945 0.335
AST U/L 40.6 ± 11.4 39.8 ± 10.6 0.075 0.785
TBil Hmol/L 22.5 ± 9.0 21.6 ± 7.4 0.164 0.687
SCr Hmol/L 96.2 ± 18.7 97.4 ± 20.6 0.058 0.810
Note: Data were presented as mean ± SE. Analysis of variance was used to compare
the difference between groups. ALT: Alanine aminotransferase, AST: Aspartate
aminotransferase, TBil: Total bilirubin, SCr: Serum creatinine.2.3.2. Exclusion criteria
Patients participating in other clinical trials; pregnant and
lactating women; women of childbearing age who do not agree to
use contraception during the experiment; patients with severe
pneumonia, tuberculosis, pulmonary abscess, myocarditis, and
other malignant tumors; patients with severely impaired heart,
liver, and kidney function (Heart function grades 3 to 4, ALT and/or
AST more than 2 times the normal upper limit, SCr exceeded the
normal upper limit); patients with mental illness and unable to
cooperate; patients without obtained informed consent; patientswith Grade IV bone marrow suppression after any cycle of
chemotherapy; patients who the investigator determined not
appropriate for the trial.2.4. Treatment
Chemotherapy was given to the patients according to the NCCN
Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung
Cancer (Chinese version). The G-CSF group was given PEG-rhG-CSF
subcutaneously 48 hours after the commencement of each cycle of
chemotherapy; the GEJ group received GEJ orally at a dose of 10 g
twice daily 48 hours after each cycle of chemotherapy for 14 days.
GEJ was prepared traditionally using tortoise shell gum, antler gum,
red ginseng, and wolfberry boiled for 2 hours at a ratio of 32: 16: 6:
3. All Chinese herbal medicines used in this study were provided by
the Guangzhou Chinese Herbal Medicine Company (Guangzhou,
China).2.5. Safety assessment
Number of participants with adverse events (AE) and dose
limiting toxicities of GEJ were assessed according to CTCAE v4.0.2.6. Analysis of liver and kidney function, and routine blood count
Serum ALT, AST, direct, indirect and total bilirubin (TBil), and
SCr were determined before the commencement of chemotherapy
and again the third week of the 4th cycle of chemotherapy by
hospital standard enzymatic procedures using an automated
bioanalyzer (Hitachi, Tokyo, Japan). Routine blood counts (red
blood cells (RBC), hemoglobin (HGB), while blood cells (WBC), and
platelets (PLT)) were conducted using a hospital automated
bioanalyzer.2.7. Statistical analysis
Data analysis was performed using SPSS 22.0 software. Chi-
square test was used for gender and disease staging analysis.
One-way ANOVAwas used for analysis of HGB,WBC, and PLTcounts
in different groups. P < 0.05 was considered statistically significant.
Fig. 1. Hematological profiles (white blood cells, hemoglobin, and platelet) at various
timepoints following treatments. A: Before chemotherapy; B: on completion of 1st
cycle of chemotherapy; C: 1 week after 1st cycle of chemotherapy; D: before 2nd cycle
of chemotherapy; E: On completion of 2nd cycle of chemotherapy; F: before 3rd cycle
of chemotherapy; G: One week after 3rd cycle of chemotherapy; H: Before 4th cycle of
chemotherapy; I: One week after 4th cycle of chemotherapy; J: Three weeks after 4th
cycle of chemotherapy. **P < 0.01, ***P < 0.001.
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3.1. Baseline information of the patients
There was no statistical difference in the indexes between the
two groups, GEJ and G-CSF (Table 1). From the table, the sex ratio
and age of onset of these groups are similar to the overall incidence
of lung cancer, indicating that these two groups of cases are
comparable.3.2. Safety profile of GEJ
During the course of this study, following continuous adminis-
tration of GEJ for 4 cycles of chemotherapy, no observed AE/toxic
reaction was found associated with the use of GEJ (Table 2). Alsoshown in Table 2, there was no significant difference in liver and
kidney functions between the GEJ group and the G-CSF group.
3.3. Hematological profile following treatment
As shown in Fig. 1, there was no significant difference between
the GEJ group and the G-CSF group in HGB and PLT. Following
chemotherapy, WBC decreased significantly after 1 cycle of
chemotherapy (P < 0.01); WBC increased significantly after treat-
ment with GEJ or G-CSF (P < 0.01 or 0.001). The magnitude of in-
crease in WBC in the G-SCF group is much more significant than
that in GEJ group at multiple time points (C, D, E, F,G and I, p < 0.001
in all comparisons), indicating that G-CSF at the recommended
dosage stimulated bone marrow much stronger that by GEJ treat-
ment. In the GEJ treatment group, WBC counts significantly
increased after GEJ treatment achieving WBC levels similar to WBC
counts taken prior to chemotherapy (p < 0.01). Thereafter, the GEJ
patient group maintained WBC stability, from one week after the
first cycle of chemotherapy to the end of the study (from C to J,
Fig. 1).
In summary, our data showed that the safety profile of oral GEJ is
identical to that of PEG-rhG-CSF given subcutaneously. There was
no indication, in this study, that long term use of herbal medicine
causes impairment of liver and kidney. Both GEJ and G-CSF effec-
tively increased WBC in lung adenocarcinoma patients receiving a
standard 4 cycles of chemotherapy. In the group treated with GEJ,
WBC increase was much steadier, compared to the highly fluctu-
ating changes observed in the G-CSF group. Our findings suggest
that GEJ may be a better alternative to treat myelosuppression in
patients receiving cancer chemotherapy. Treating patients with GEJ
may help in the prevention of bone marrow failure due to excessive
stimulation and mobilization of bone marrow as observed in pa-
tients receiving PEG-rhG-CSF. Thus, further research is warranted
to investigate the underlying mechanism of GEJ as an alternative
therapy to treat chemotherapy-induced myelosuppression.
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